PROM1 and colorectal carcinoma: Indeed, the findings of a phase I clinical trial (NCT02541370) indicated that infusion of autologous CAR-T-cell-directed CD133 (CART-133) inhibits disease progression in patients with advanced metastatic lung, liver, and colorectal carcinoma [264].